Company: CRL
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001100682-25-000011
Chunk: 132

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-02-19
Form: 10-K
Item: Item 8
Chunk 132
---
 on venture capital and strategic equity investments, net12,910 (97,827)26,775 Provision for credit losses14,774 18,225 6,706 Loss (gain) on divestitures, net659 961 (123,405)Other, net33,251 1,079 16,118 Changes in assets and liabilities:   Trade receivables and contract assets, net21,612 (33,434)(150,570)Inventories16,804 (62,301)(78,523)Accounts payable(14,271)(20,427)(2,652)Accrued compensation(27,604)12,447 (42,164)Deferred revenue18,541 (21,743)57,658 Customer contract deposits6,584 (15,564)30,457 Other assets and liabilities, net(51,995)38,642 33,240 Net cash provided by operating activities734,577 683,898 619,640 Cash flows relating to investing activities   Acquisition of businesses and assets, net of cash acquired(5,479)(194,785)(283,392)Capital expenditures(232,967)(318,528)(324,733)Purchases of investments and contributions to venture capital investments(52,876)(54,215)(158,274)Proceeds from sale of investments41,687 6,667 4,549 Proceeds from sale of businesses, net— — 163,275 Other, net4,549 (2,294)(9,347)Net cash used in investing activities(245,086)(563,155)(607,922)Cash flows relating to financing activities   Proceeds from long-term debt and revolving credit facility1,081,581 776,353 2,952,430 Proceeds from exercises of stock options23,878 25,597 25,110 Payments on long-term debt, revolving credit facility, and finance lease obligations(1,493,769)(851,676)(2,932,636)Purchase of treasury stock(119,175)(24,155)(38,651)Payments of contingent consideration— (2,711)(10,356)Purchase of remaining equity interest of other redeemable noncontrolling interest(12,000)(4,784)(30,533)Other, net(31,442)(4,145